Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.

MLA

Smith, Michael P., et al. “Targeting Endothelin Receptor Signalling Overcomes Heterogeneity Driven Therapy Failure.” EMBO Molecular Medicine, vol. 9, no. 8, Aug. 2017, pp. 1011–29. EBSCOhost, https://doi.org/10.15252/emmm.201607156.

APA

Smith, M. P., Rowling, E. J., Miskolczi, Z., Ferguson, J., Spoerri, L., Haass, N. K., Sloss, O., McEntegart, S., Arozarena, I., von Kriegsheim, A., Rodriguez, J., Brunton, H., Kmarashev, J., Levesque, M. P., Dummer, R., Frederick, D. T., Andrews, M. C., Cooper, Z. A., Flaherty, K. T., … Wellbrock, C. (2017). Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Molecular Medicine, 9(8), 1011–1029. https://doi.org/10.15252/emmm.201607156

Chicago

Smith, Michael P, Emily J Rowling, Zsofia Miskolczi, Jennifer Ferguson, Loredana Spoerri, Nikolas K Haass, Olivia Sloss, et al. 2017. “Targeting Endothelin Receptor Signalling Overcomes Heterogeneity Driven Therapy Failure.” EMBO Molecular Medicine 9 (8): 1011–29. doi:10.15252/emmm.201607156.